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BIOPHYSICAL ANALYSIS AND NMR STRUCTURAL CHARACTERIZATION 
OF THE BINDING BETWEEN PEPTIDOMIMETIC DRUG CN2097 AND 
SCAFFOLDING PROTEIN PSD-95 
TONY KEN HU 
ABSTRACT 
Background: At the postsynaptic membrane of neurons there is a dense network of 
proteins called the postsynaptic density (PSD). One such protein is the postsynaptic 
density protein 95 (PSD-95), which functions as a molecular scaffold for forming protein 
complexes at the PSD. PSD-95 is composed of three PDZ domains, which studies have 
shown to be sequentially and structurally similar. Studies have shown that PSD-95 plays 
a role in regulating signaling of glutamatergic neurons, as well as the induction of long-
term potentiation through an association with TrkB receptors. PSD-95 may be a 
promising target for treatment of a number of neurological disorders such as depression, 
epilepsy, and cognitive dysfunction. The cyclic peptidomimetic drug CN2097 was 
designed based on the PDZ-binding motif of the CRIPT protein that binds to PDZ3. 
While CN2097 has been shown to affect the binding of PSD-95 to different synaptic 
proteins, no NMR studies have been performed to characterize the binding of CN2097 to 
PDZ3.  Furthermore, few studies have characterized the inter-domain interactions 
between PDZ domains or whether the binding of calmodulin (CaM) to the N-terminal 
region of PSD-95 has any effect on the binding between the PDZ domains and CN2097. 
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Objective: To use isothermal titration calorimetry and nuclear magnetic resonance 
spectroscopy to analyze and characterize how CN2097 binds to PDZ domains and 
whether inter-domain interactions exist between PDZ domains. 
Methods: The gene sequences for the PDZ domains were inserted into the pET28a(+) 
vector by subcloning. E. coli bacteria were then transformed with the different PDZ 
plasmids. The bacterial cells were grown and induced to express the proteins of interest,  
followed by lysis and purification using affinity chromatography and fast protein liquid 
chromatography (FPLC). Isothermal titration calorimetry (ITC) was used to measure the 
dissociation constant and thermodynamic binding parameters between the 
peptidomimetic drug CN2097 and each isolated PDZ domain. Nuclear magnetic 
resonance (NMR) spectroscopy was used to study how CN2097 binds to PDZ1 and 
PDZ3, and how the PDZ domains interact with each other. 
Results: The ITC data showed the dissociation constant between CN2097 and PDZ3 to 
be 5.12 ± (1.65) µM, and that of PDZ2+3 to be 42.63 ± (6.11)µM. ITC data on other 
domains was inconclusive. The NMR data showed no interaction between N-terminal 
region and PDZ1, and between PDZ2 and PDZ3 but significant interaction was seen 
between PDZ1 and PDZ2, as well as between PDZ3 and the inter-domain linker 
connecting it to PDZ2. NMR data showed that CN2097 binding perturbs PDZ3 more 
strongly than PDZ1 and that CN2097 does not bind to PDZ1 in the presence of CaM. 
Significant NMR chemical shift perturbations are seen on the second α-helix, second β-
sheet, and β2-β3 loop. 
  viii 
Conclusions: There are no significant contacts between the N-terminal α-helix and 
PDZ1. There is inter-domain conformational exchange and interaction between PDZ1 
and PDZ2. PDZ3 interacts with the second inter-domain linker. CN2097 binds tighter to 
PDZ3 than to PDZ1, and does not bind to PDZ1 in the presence of CaM. The β2-β3 loop 
is a prime target for future development of CN2097. 
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INTRODUCTION 
 
Postsynaptic density protein 95 and PDZ domains 
The postsynaptic density (PSD) is a dense network of proteins located at the 
postsynaptic membrane, which has a vast array of roles, from signaling pathways to 
regulating structural changes (Boeckers, 2006). One of the many PSD proteins is 
postsynaptic density protein-95 (PSD-95), also known as synapse associated protein-90 
(SAP-90), which is a scaffolding protein that plays a role in the localization and 
clustering of synaptic proteins (Piserchio et al., 2004). The synaptic proteins that interact 
with PSD-95 play a role in synaptic plasticity, which is affected in a wide range of 
neurological and cognitive, such as Alzheimer’s disease, autism, schizophrenia, and 
chronic pain (Bliss, Collingridge, & Morris, 2014). 
PSD-95 consists of five domains: three PDZ domains (initialism of PSD-95, 
Drosophila disc large, and Zonula occludens-1), an Src 3 (SH3) domain, and a guanylate 
kinase-like domain (Kim & Sheng, 2004). In addition to these five domains, there are two 
calmodulin (CaM)-binding regions, one on the N-terminal region (Zhang et al., 2014), 
and one on the region connecting SH3 and the guanylate kinase-like domain, also known 
as the HOOK region (Paarmann, Spangenberg, Lavie, & Konrad, 2002). Nuclear 
magnetic resonance (NMR) studies have revealed that the two lobes of CaM bind to 
PSD-95 by collapsing around the helical structure of the N-terminus of PSD-95 (Zhang et 
al., 2014). Under basal conditions, PSD-95 cycles between palmitoylation and 
depalmitoylation with the postsynaptic membrane (Fukata et al., 2013; Zhang et al., 
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2014). Upon binding, CaM masks residues C3 and C5 of PSD-95, preventing 
palmitoylation of PSD-95 and shifting the equilibrium towards depalmitoylation (Zhang 
et al., 2014). In addition to the N-terminal and HOOK regions, CaM has been shown to 
also bind the PDZ2 and SH3 domains, but not the PDZ3 and guanylate kinase domains 
(Paarmann et al., 2002; Zhang et al., 2014). It is unknown whether CaM binds to PDZ1. 
The binding of CaM to the various domains could have potential implications when 
studying PDZ-binding drugs, as the binding of CaM to the N-terminal helix, PDZ2, SH3, 
and/or PDZ1 (if it binds at all) may potentially interfere with any drug or ligand binding. 
The PDZ domain is found in over 200 proteins and contains between 80-100 
residues (Lee & Zheng, 2010; Ponting, 1997). The three PDZ domains of PSD-95 have 
been shown to be highly similar both sequentially and structurally, in that they share the  
have similar fold created by two α-helices and six β-strands (Piserchio et al., 2004). PDZ 
domains bind to the C-terminal region of proteins containing the sequence motif 
(Ser/Thr)-X-(Val/Ile/Leu)-COOH (X being any amino acid) and is characteristic of the 
rapid association and dissociation between ligand and receptor as found in cell receptor 
signaling (Piserchio et al., 2004). The binding cleft is located between the second β-
strand and the second α-helix (Doyle et al., 1996). Despite their similarity, each PDZ 
domain has a different preference for binding partners, and the origin to their individual 
specificity is unknown. The loop between the second and third β-strands in PDZ1 and 
PDZ2 has been shown through NMR studies to be affected during ligand association 
(Piserchio et al., 2002; Tochio, Hung, Li, Bredt, & Zhang, 2000), which potentially may 
play a part in the binding mechanism and/or specificity. It is also unclear whether there 
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are any inter-domain interactions between the PDZ domains, such as, between the N-
terminal CaM-binding helix and PDZ1, and between PDZ2 and PDZ3. 
 
Biological role of PSD-95 protein 
As mentioned above, PSD-95 plays a role in the localization and clustering of 
synaptic proteins. An example of this is the association of PSD-95 with receptors to 
activate different signaling pathways. PSD-95 is known to associate with kainate 
receptors, N-methyl-D-aspartate (NMDA) receptors, and tropomyosin-related kinase B 
(TrkB) receptors (Cao et al., 2013; Garcia et al., 1998; Sornarajah et al., 2008), as well as 
indirectly regulating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor surface trafficking (Bats, Groc, & Choquet, 2007).  However, the mechanisms of 
how PSD-95 regulates receptor targeting, clustering, and facilitation of signaling are not 
entirely understood.  
Kainate receptors are known to play a role in epilepsy, autism, and schizophrenia 
(Lerma & Marques, 2013). When coexpressed in HEK293 cells, PSD-95 has been found 
to promote the clustering of the GluK2 (GRIK2, GluR6) kainate receptor (Garcia et al., 
1998). Indeed, PSD-95 has been found to serve as a scaffold of kainate receptors at 
hippocampal mossy fiber synapses (Suzuki & Kamiya, 2016). The activation of kainate 
receptors with GluK1 (GRIK1, GluR5) subunits has been shown to trigger seizures, 
although they are not necessary for their generation (Fritsch, Reis, Gasior, Kaminski, & 
Rogawski, 2014). The mechanism of kainate receptor clustering and targeting is not fully 
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understood. However, kainate receptors and the role PSD-95 plays are both topics of 
interest in the development of therapeutic drugs for the treatment of epilepsy. 
As for NMDA receptors, it has been discovered that the direct binding of PDZ1 
and PDZ2 domains of PSD-95 to the NR2A- or NR2B-containing subunits of NMDA 
receptors reduces desensitization of neuronal and non-neuronal cells (Sornarajah et al., 
2008). NMDA receptor desensitization may protect against excitotoxicity caused by Ca2+ 
influx under repeated glutamate insult (Sornarajah et al., 2008), which plays a role in the 
severity of ischemic brain damage from stroke in animals (Aarts et al., 2002). NMDA 
receptor antagonists seemingly are not viable as therapeutic targets (Davis et al., 2000; 
Fix et al., 1993), but targeting the PDZ domains of PSD-95 as a means to decrease its 
association with NMDA receptors may be a potential therapeutic option for minimizing 
ischemic brain damage. 
PSD-95 has been shown to interact with stargazin, a regulatory protein that 
associates with and localizes AMPA receptors to the PSD (Bats et al., 2007). The 
ubiquitination of PSD-95 in response to the activation of NMDA receptors untethers 
AMPA receptors from the postsynaptic membrane, allowing for their endocytosis and 
removal from synaptic sites (Colledge et al., 2003), essentially downregulating AMPA 
receptor signaling. A study has shown that an AMPA receptor antagonist, perampanel, 
was effective as an adjunctive treatment for epileptic seizures (French et al., 2013), 
supporting the concept that AMPA receptors are critical in epileptic synchronization and 
in the generation of epileptic discharges in humans (Rogawski, 2013). As PSD-95 plays a 
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role in the localization of AMPA receptors to the PSD, it may be worthy of being a target 
for developing treatments for epilepsy as well. 
It has been shown that PSD-95 association with TrkB receptor is critical for brain-
derived neurotrophic factor (BDNF) TrkB signaling, which is known to induce and 
maintain long-term potentiation (LTP), a form of synaptic plasticity that is involved in 
cognitive function (Cao et al., 2013). A proposed possible role of PSD-95 in BDNF-
derived TrkB signaling is that upon binding of BDNF to TrkB, PSD-95 is recruited to the 
receptor to facilitate downstream signaling (Cao et al., 2013). Following traumatic brain 
injury, BDNF is dysregulated (Marshall et al., 2017), and in neurological disorders such 
as Angelman syndrome, BDNF-derived TrkB signaling is impaired by the interference of 
elevated levels of activity-regulated cytoskeletal-associated protein (Arc; Cao et al., 
2013). There has been development of a drug, CN2097, as a potential therapeutic that 
binds to the PDZ domains of PSD-95, decreasing its interaction with Arc (Cao et al., 
2013). 
There is a great deal about PSD-95 that is unknown. Kainate, AMPA, NMDA, 
and TrkB receptors are only a few of the known synaptic membrane proteins that PSD-95 
interacts with; the extent of PSD-95 interactions with other synaptic proteins in the PSD 
remains unclear. Because of its involvement in a wide range of protein complexes at the 
postsynaptic membrane, any potential therapeutic agents targeting PSD-95 will require a 
wide range of experiments to decrease the amount and severity of any inadvertent side 
effects. 
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Peptidomimetic drug CN2097 
As mentioned before, a ligand that binds to PSD-95 could be a potential 
therapeutic agent for epilepsy, reducing stroke-associated ischemic brain damage, and the 
mitigation of cognitive dysfunction. A cyclic peptide based on the C-terminal six residues 
of the CRIPT protein was designed to bind to PDZ3 of PSD-95 (Li, Saro, & Spaller, 
2004). The CRIPT protein is a linear peptide that has been structurally characterized to 
bind to PDZ3 (Niethammer 1998), the primary binding residues being the C-terminal (P0) 
and the antepenultimate (P-2) residues (Li et al., 2004). A bridging approach was used 
when designing the peptide, creating a β-Ala lactam linker in order to overcome the 
unfavorable distortion on the peptide backbone by way of covalently connecting the P-1 
and P-3 residues so as to exhibit overall conformational diversity (Li et al., 2004). 
Aside from binding to PDZ3, another study has shown that the cyclic peptide also 
binds to PDZ1 of PSD-95 (Piserchio et al., 2004). The sequence motif that binds to the 
PDZ domains is known and was previously described above. Piserchio et al. (2004) 
performed NMR spectroscopy on the titration of PDZ1 with the cyclic peptide and 
showed the amino acid residues that are affected during binding (Figure 1). However, no 
such experiment was conducted on PDZ3, which was the target when the cyclic peptide 
was designed. LeBlanc et al. (2010) designed and synthesized the drug CN2097 by 
adding a polyarginine moiety to the N-terminus of the cyclic peptide, thus improving the 
permeability of the cyclic peptide across cellular membranes.   
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Figure 1: Binding of CN2097 to PDZ1. The specific residues involved in the binding of 
CN2097 to PDZ1 are labeled and depicted here in dark green (Piserchio et al., 2004). 
 
As mentioned, it is unknown whether CaM binds to PDZ1 or whether CaM 
interferes with the binding of CN2097 to the PDZ domains. Previously, a concentration 
of 400µM CRIPT peptide was shown to enhance the binding between PSD-95 and CaM 
(Fukunaga, Matsubara, Nagai, & Miyazawa, 2005). Although the CRIPT peptide only 
binds PDZ3 and the design of CN2097 was based on CRIPT, it is unknown if CN2097 
elicits a similar effect. 
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Isothermal titration calorimetry and its use 
 Isothermal titration calorimetry (ITC) is a technique that is used to study protein-
protein, protein-small molecule, protein-DNA/RNA interactions, enzyme kinetics, as well 
as protein folding and unfolding (Liang, 2008). It is the only technique that directly 
determines the thermodynamic parameters of a reaction: the enthalpy change (∆H), the 
change in Gibbs free energy (∆G), the entropy change (∆S), and the heat capacity change 
in the process (∆Cp) (Velazquez-Campoy, Leavitt, & Freire, 2004). When studying 
protein-protein interactions, the binding partners can be different proteins or even the 
same protein (i.e., homodimer). Regardless of the type of interaction or binding partners 
involved, the underlying principles of ITC are the same.  
When a ligand and a protein bind, there is a change in the enthalpy, free energy, 
and entropy that can be measured through an increase or decrease in temperature. During 
an ITC experiment, stepwise injections of the ligand are added into a calorimetric cell via 
a syringe (Velazquez-Campoy et al., 2004). The cell is maintained at a constant 
temperature. As the ligand is injected and binds to the protein, small changes in 
temperature are measured as different changes in energy supplied to the cell. The 
association constant Ka, the stoichiometric number N, and the change in enthalpy ∆H can 
all be determined based on the heat changes, cell concentrations, and syringe 
concentrations. From those values, ∆G, ∆S, ∆Cp, and the dissociation constant Kd can 
also be estimated. In addition to the experiment of adding the ligand to the protein, a 
blank experiment of adding ligand to buffer is required to account for the contribution of 
the enthalpy of dilution. 
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 When designing the cyclic peptide portion of CN2097, ITC was used to measure 
the dissociation constant between the cyclic peptide and PDZ3 (Li et al., 2004), which 
indicated whether or not there was binding between the peptide and PDZ3. ITC is used in 
this study to characterize drug CN2097 binding to all three PDZ domains. 
 
Biomolecular NMR spectroscopy and its use 
 While ITC is useful to observe the binding of a ligand to a protein, it is rather 
crude when compared to NMR spectroscopy in terms of determining whether binding 
happens or not. NMR spectroscopy is the technique for determining the structure of a 
molecule, in this case the protein and the peptidomimetic drug. NMR spectroscopy works 
by detecting the electromagnetic waves that are generated by nuclei when they are 
subjected to a magnetic field, and a weaker, oscillating magnetic field (Doucleff, 
Hatcher-Skeers, & Crane, 2011). Different nuclei are affected invariably by the magnetic 
field, as the surrounding electrons tend to lower or negate the effects of the external 
magnetic field. Neighboring atoms, depending on their electronegativity, will therefore 
have varying effects on the signals through J-coupling if covalently bonded, or dipole-
dipole coupling if less than 5Å apart (Doucleff et al., 2011). The effects of J-coupling can 
be analyzed using heteronuclear single-quantum coherence correlation spectroscopy 
(HSQC) and the effects of dipole-dipole coupling can be analyzed using nuclear 
Overhauser effect spectroscopy (NOESY).  
For biological NMR spectroscopy, signals produced by hydrogen, nitrogen, and 
carbon atoms are most useful in characterizing the structures of proteins. However, only 
 10 
nuclei with spins of ½ (e.g., 1H, 13C, and 15N) generate signals that can be easily 
analyzed. Nuclei with a spin of zero (e.g., 12C) generate no signals, and nuclei with spins 
greater than ½ (e.g., 14N) generate signals that are too short, dampened, and difficult to 
detect due to their electric quadrupolar moment (Doucleff et al., 2011). Obtaining just the 
1D- 1H spectrum of protein samples is not very informative due to signal overlap. 
Instead, obtaining a 2D- 1H-15N HSQC spectrum shows protons that are covalently 
bonded to nitrogen atoms, while an 2D- 1H-13C HSQC spectrum shows protons that are 
covalently bonded to carbon atoms (Doucleff et al., 2011). Because of this, when 
expressing proteins for NMR, M9 media, which contains 15N-labeled ammonium 
chloride, is used to grow cells in conjunction with the optional addition of 13C-labeled 
glucose. When both are used, triple resonance experiments can be conducted to provide 
assignments of individual residues in a protein. Two such triple resonance experiments 
are 3D- HNCA and 3D- HNCO, both of which were used in this study. HNCA correlates 
the amide 1H and 15N shifts of a residue with the Cα shifts of a residue as well as the 
preceding residue, while HNCO correlates the amide shifts of a residue with the carbonyl 
carbon shift of the preceding residue (Kay, Ikura, Tschudin, & Bax, 1990).  
In this study, 2D- HSQC was used to structurally characterize the binding 
between CN2097 and the isolated PDZ domains as well as to characterize inter-domain 
interactions between PDZ domains. The HSQC experiments served to supplement the 
ITC data acquired on the binding between CN2097 and the PDZ domains and provided 
residue-specific information about the binding interface. The spectrum can be analyzed to 
show which amino acids are affected upon binding. Each amino acid generates a distinct 
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signal that would change upon binding. The 1H-15N HSQC spectra would change if 
CN2097 bound to a PDZ domain or if inter-domain interactions are present. Normally, 
performing a titration of protein with a ligand would show how each residue is affected 
during binding and can be used to calculate the apparent dissociation constant (EC50), 
but this was not conducted as we have more accurate information from the ITC 
experiment. HNCA and HNCO experiments were performed on the PDZ3/CN2097 
complex in addition to 2D total correlation spectroscopy (TOCSY) being performed on 
CN2097. The purpose of these experiments was to obtain backbone and side-chain 
assignments for the PDZ3/CN2097 complex. The assignments would eventually allow 
for calculating the 3D structure of the PDZ3/CN2097 complex, which would be 
immensely helpful for the future development of the drug.
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MATERIALS AND METHODS 
 
Cells, plasmids, and peptidomimetic drug 
 BL21 (DE3) competent E. coli cells were used for the protein expression 
necessary for this experiment. pGEX-4T1 PDZ domain plasmids and the peptidomimetic 
drug CN2097 were provided by Dr. John Marshall of the Department of Molecular 
Pharmacology, Physiology and Biotechnology at Brown University. These plasmids 
contained the gene for one the following PDZ domains of PSD-95: PDZ1 with the N-
terminal CaM-binding region (PDZ1long), PDZ2, PDZ3, the combined domains of PDZ1 
and PDZ2 (PDZ1+2), and the combined domains of PDZ2 and PDZ3 (PDZ2+3). The 
residue numbers of PSD-95 that each recombinant protein contained can be seen in 
Figure 2. PDZ1long extended from residues 1-151, PDZ1 from residues 65-151, PDZ2 
from 160-246, PDZ3 from 313-393, PDZ1+2 from 65-246, PDZ2+3 from 160-393, and 
PDZ1+2+3 from 1-393. In addition, a pET11d-PDZ1 plasmid was used in this study. 
Calmodulin plasmid was obtained from Addgene. 
 
Figure 2: Domain Architecture of PSD-95. The residue numbers of the different PDZ 
domains is shown here, in addition to all the domains and regions of PSD-95. The linkers 
and domains are not shown to scale. 
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Subcloning PDZ genes into pET28a(+) vector 
BL21 (DE3) cells were initially transformed with the GST fusion plasmids with 
the intention of expressing the PDZ domains with a N-terminal glutathione S-transferase 
(GST) tag and thrombin-cutting site. However, the thrombin protease failed to fully 
cleave the GST tag from the PDZ domains and lead to degradation of the PDZ protein. 
The gene corresponding to the domains in each of these plasmids were amplified by PCR 
and subcloned into the pET-28a(+) recombinant vector. The restriction enzymes EcoRI 
and SalI were used for PDZ1, PDZ3, and PDZ2+3. The restriction enzymes EcoRI and 
XhoI were used for PDZ2 and PDZ1+2. The success of creating new plasmid vectors was 
determined by DNA sequencing. In addition a plasmid was created, containing all three 
PDZ domains as well as the N-terminal CaM-binding region (PDZ1+2+3).  
 
Expressing PDZ domains and CaM 
 A 1µL aliquot of each plasmid was used to transform ~50µL of BL21 cells. The 
cells were then transferred in 25mL LB media starter cultures and incubated at 37˚C, 
300rpm overnight. The starter cultures were then added to 800mL LB media and 
incubated at 37˚C, 200rpm until the OD600 reached 0.4-0.8, at which point isopropyl β-D-
1-thiogalactopyranoside (IPTG) was added for a working concentration of 0.5mM, and 
further incubated for 3 to 4 hours. A similar protocol was followed for expressing the 
15N-labeled and 15N/13C-labeled protein, with the only exception being the use of M9 
media supplemented with 15NH4Cl or 15NH4Cl/13C-glucose instead of LB media. 
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Protein purification 
 For the PDZ domains and CaM, the 800mL cell cultures were centrifuged at 
4000rpm, 4˚C until a cell pellet formed, at which point the media was discarded and the 
pellet re-suspended in high salt buffer (pH=8.0, 1M NaCl, 50mM KH2PO4). Cells were 
lysed by adding Triton X-100 (1µL/mL of cell suspension) and by sonication. 
Phenylmethylsulfonyl fluoride (PMSF) in isopropanol was added at a final concentration 
of 100-150µM to inhibit protein breakdown by bacterial serine proteases. The cell lysate 
suspension was centrifuged at 14,000rpm, 4˚C until a pellet formed.  
Each PDZ domain contained a polyhistidine (His) tag, and therefore the cell 
lysate for those proteins was purified by immobilized metal ion affinity chromatography 
(IMAC). The cell lysate of the PDZ domains were passed on fast protein liquid 
chromatography (FPLC) with a HisPrep™ Fast Flow 16/10 column. All proteins in 
IMAC were eluted using 50mM potassium phosphate buffer with 100mM NaCl and 
250mM imidazole (pH 7.5). The presence of the correct protein was determined by 
polyacrylamide gel electrophoresis. All protein samples were then concentrated to a total 
volume of ~5mL. All proteins needed to be purified by size-exclusion chromatography 
(SEC) to eliminate the presence of imidazole, and therefore were passed on FPLC with a 
HiLoad® 16/600 Superdex® 75 column using 50mM potassium phosphate buffer with 
100mM NaCl (pH=7.5). All protein samples were then concentrated to ≤2mL. The purity 
of the protein was also checked by polyacrylamide gel electrophoresis. 
A similar protocol was followed for purifying CaM. Since CaM was expressed 
with a GST-tag, it was first purified on FPLC with a GSTPrep™ Fast Flow 16/10 
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column. Thrombin was used to cleave the GST-tag from CaM before being purified by 
SEC. 
 
ITC experiments and analysis 
 The concentration of each purified protein sample was determined by measuring 
the UV absorption of each sample at 280nm using a spectrophotometer and calculating 
the concentration based on Beer’s Law. Experiments were performed with an iTC200 
titration microcalorimeter (Microcal, Inc.). The drug CN2097 was weighed out and 
dissolved in the same buffer used during SEC, for a concentration of 1mM. All ITC 
experiments were conducted at 25˚C in 50mM potassium buffer with 100mM NaCl 
(pH=7.5) and all solutions were degassed. The typical titration had the ligand (~1mM) 
injected into isolated PDZ domains (100µM), with the exception of three titrations of 
PDZ2+3, which were conducted with a protein concentration of 50µM. ITC experiments 
were conducted on PDZ1long, PDZ1, PDZ2, PDZ3, PDZ1+2, and PDZ2+3. The heat of 
dilution was measured with a blank titration of the ligand into the buffer, and subtracted 
from each titration experiment. All ITC data was analyzed using Origin software (version 
5.0, Microcal). 
 
NMR spectroscopy and residue assignments 
All NMR spectra were collected at 20˚C using a Bruker NEO 600MHz 
spectrometer. 1H-15N HSQC experiments were performed on the following: PDZ1long, 
PDZ1, PDZ2, PDZ3, PDZ1+2, PDZ2+3, PDZ1+2+3, PDZ1/CN2097 complex, 
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PDZ3/CN2097 complex, PDZ1long/CaM complex, and PDZ1long/CaM/CN2097 
complex. In addition to HSQC experiments, 3D- HNCA and 3D HNCO experiments 
were both performed on PDZ3 and PDZ3/CN2097 complex and a 2D- TOCSY 
experiment was performed on CN2097. The final concentration ratio of CaM to 
PDZ1long was 1:1, and the final concentration ratio of the PDZ domain complex to 
CN2097 was also 1:1. NMRFAM-Sparky was used to analyze the 3D spectra to assign 
amino acid residues. 
The NMR experiments of the PDZ1long-CaM complex and the PDZ1long-CaM 
complex with CN2097 were conducted with a 500µL solution containing 74µM 15N 
labeled PDZ1long protein, 74µM unlabeled CaM protein, and 74µM CN2097 in 50mM 
potassium phosphate buffer, 100mM NaCl (pH 7.5), and 10% (v/v) D2O. Other NMR 
experiments were conducted similarly with protein concentrations ~100µM and the 
protein to CN2097 ratios was 1:1. 
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RESULTS 
 
ITC results of CN2097 binding to PDZ domains 
The ITC experiments were inconclusive in determining binding parameters for 
PDZ1long, PDZ1, PDZ2, and PDZ1+2. The generation of heat from multiple 
experiments involving PDZ1long, PDZ1, PDZ2, and PDZ1+2 was too little to reliably 
determine binding parameters. ITC data was insufficient to determine how the N-terminal 
CaM-binding region affects the binding of CN2097 to PDZ1, as well as how PDZ2 
affects the binding of CN2097 to PDZ1. 
The dissociation constant of PDZ3 was determined to be 5.12 ± (1.65) µM. The 
dissociation constant of PDZ2+3 was determined to be 42.63 ± (6.11) µM. Table 1 
displays the values of the other binding parameters for PDZ3 and PDZ2+3. The ITC data 
of PDZ3 and PDZ2+3 that was used in determining their thermodynamic parameters can 
be seen in Figure 3 and Figure 4. The lower dissociation constant of PDZ3 compared to 
PDZ2+3 indicates that CN2097 binds to isolated PDZ3 more tightly. 
Table 1. Thermodynamic Parameters of the Binding of CN2097 to PDZ domains 
from PSD-95A 
PDZ Domain Kd (µM) ∆G (kcal/mol) ∆H (kcal/mol) T∆S (kcal/mol) 
PDZ1long B – – – – 
PDZ1B – – – – 
PDZ2B – – – – 
PDZ3 5.12 ± (1.65) -3.63 ± (0.17) -3.30 ± (0.20) 0.33 ± (0.03) 
PDZ1+2B – – – – 
PDZ2+3 42.63 ± (6.11) -6.55 ± (0.88) -6.61 ± (0.97) -0.05 ± (0.09) 
A Values are the average of two independent experiments performed at 25˚C.  
B The generation of heat for multiple experiments was too small to reliably determine 
binding parameters. 
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Figure 3. ITC thermogram of the titration of 100µM PDZ3 with 1mM CN2097. 
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Figure 3 continued. ITC thermogram of the titration of 100µM PDZ3 with 1mM 
CN2097. 
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Figure 4. ITC thermogram of the titration of 50µM PDZ2+3 with 1mM CN2097. 
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Figure 4 continued. ITC figures of the titration of 50µM PDZ2+3 with 1mM 
CN2097. 
 
NMR spectroscopy of PDZ inter-domain interactions 
 Residue specific snapshots of isolated PDZ domain structures were obtained by 
NMR 15N-HSQC spectrum (Figure 5). The resonance peaks of PDZ1, PDZ2, and PDZ3 
are monodispersed and well resolved, indicating that each domain is well folded in 
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solution. Based on the different HSQC spectrum of each isolated domain, it can be 
determined that the domains are considerably different from each other.   
 
Figure 5: 15N-HSQC spectrum of PSD-95 isolated PDZ domains. Each peak denotes a 
backbone amide of a non-proline residue or side chains of Asn, Arg, Gln, and Trp.  
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Figure 5 continued: 15N-HSQC fingerprinting of PSD-95 isolated PDZ domains. 
Each peak denotes a backbone amide of a non-proline residue or side chains of Asn, Arg, 
Gln, and Trp.  
 
 24 
 A residue specific snapshot of PDZ1long structure was obtained by NMR 15N-
HSQC spectrum (Figure 6). The resonance peaks of PDZ1long are monodispersed and 
well resolved, indicating that it is well folded in solution. Comparison of the HSQC of 
PDZ1long and PDZ1 by overlaying the two spectra shows that there are no significant 
perturbations in the PDZ1 peaks (Figure 7). There are additional peaks and minor 
differences that can be attributed to the addition of an N-terminal α-helix in PDZ1long, 
which is to be expected. The lack of significant perturbations indicates that the N-
terminal CaM-binding α-helix does not interact with PDZ1. 
 
Figure 6: 15N-HSQC of PDZ1long. Each peak denotes a backbone amide of a non-
proline residue or side chains of Asn, Arg, Gln, and Trp.  
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Figure 7: 15N-HSQC overlay of PDZ1 on PDZ1long. Each peak denotes a backbone 
amide of a non-proline residue or side chains of Asn, Arg, Gln, and Trp. No significant 
perturbations in PDZ1long indicate no significant contacts exist between the N-terminal 
α-helix and the PDZ1 domain. 
 
A residue specific snapshot of PDZ1+2 structure was obtained by NMR 15N-
HSQC spectrum (Figure 8). Comparison of the HSQC of PDZ1, PDZ2, and PDZ1+2 by 
overlaying the three shows that resonance peaks of PDZ1+2 have of uneven intensity 
(Figure 9). This indicates the presence of inter-domain conformational exchange and 
interaction between PDZ1 and PDZ2 domains. 
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Figure 8: 15N-HSQC of PDZ1+2. Each peak denotes a backbone amide of a non-proline 
residue or side chains of Asn, Arg, Gln, and Trp.  
 
 
Figure 9: 15N-HSQC overlay of PDZ1 and PDZ2 on PDZ1+2. Each peak denotes a 
backbone amide of a non-proline residue or side chains of Asn, Arg, Gln, and Trp. 
Uneven peak intensities indicate inter-domain conformational exchange and interaction 
between PDZ1 and PDZ2. 
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 A residue specific snapshot of PDZ2+3 structure was obtained by NMR 15N-
HSQC spectrum (Figure 10). The resonance peaks of PDZ2+3 are monodispersed and 
well resolved, indicating that it is well folded in solution. Comparison of the HSQC of 
PDZ2, PDZ3, and PDZ2+3 by overlaying the three shows that there are no significant 
perturbations in the PDZ2 region, but there are for PDZ3 (Figure 11). The specific 
perturbation in the PDZ3 region indicates that PDZ3, but not PDZ2, interacts with the 
second inter-domain linker between PDZ2 and PDZ3. 
 
Figure 10: 15N-HSQC of PDZ2+3. Each peak denotes a backbone amide of a non-
proline residue or side chains of Asn, Arg, Gln, and Trp.  
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Figure 11: 15N-HSQC overlay of PDZ2 and PDZ3 on PDZ2+3. Each peak denotes a 
backbone amide of a non-proline residue or side chains of Asn, Arg, Gln, and Trp. 
Significant perturbations in PDZ3 region indicate interaction with the second inter-
domain linker. 
 
 A residue specific snapshot of entire tri-domain PDZ region was obtained by 
NMR 15N-HSQC spectrum (Figure 12). The resonance peaks of PDZ1+2+3 are 
monodispersed, but given that there are over 300 residues, not every individual residue is 
resolved. Comparison of the HSQC of PDZ1, PDZ2, PDZ3, and PDZ1+2+3 by 
overlaying the four shows that there are some quaternary interactions between the 
individual PDZ domains (Figure 13). The binding of a drug like CN2097 to one PDZ 
domain is likely to be affected by these quaternary interactions between the domains. 
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Figure 12: 15N-HSQC of PDZ1+2+3. Each peak denotes a backbone amide of a non-
proline residue or side chains of Asn, Arg, Gln, and Trp. 
 
 
Figure 13: 15N-HSQC overlay of PDZ1, PDZ2, and PDZ3 on PDZ1+2+3. Each peak 
denotes a backbone amide of a non-proline residue or side chains of Asn, Arg, Gln, and 
Trp. Significant perturbations in PDZ1+2+3 indicate quaternary interactions among the 
PDZ domains. 
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NMR spectroscopy of PDZ/CN2097 interactions 
Residue specific snapshots of PDZ1/CN2097 complex and PDZ3/CN2097 
complex were obtained by NMR 15N-HSQC spectrum. The overlay of the HSQC of the 
PDZ3 and PDZ3/CN2097 complex shows significant perturbations in resonance peaks 
compared to the HSQC overlay of PDZ1 and PDZ1/CN2097 complex (Figure 14). The 
resonance peaks of PDZ1 have shifted after the addition of CN2097, but the peaks of 
PDZ3 after adding CN2097 shifted even more. This indicates that CN2097 binds to 
PDZ3 more strongly than to PDZ1. Statistical analysis of the chemical shift perturbations 
in the backbone amides of PDZ3 on CN2097 binding shows that the binding pocket is 
located between the second α-helix and second β-sheet, and that the β2-β3 loop is 
affected (Figure 15). 
 
Figure 14: Comparison of 15N-HSQC overlay of PDZ1 and PDZ1/CN2097 complex 
and 15N-HSQC overlay of PDZ3 and PDZ3/CN2097 complex. Each peak denotes a 
backbone amide of a non-proline residue or side chains of Asn, Arg, Gln, and Trp. 
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Greater perturbations in the PDZ3/CN2097 complex indicate stronger binding of CN2097 
to PDZ3 than to PDZ1. 
 
Figure 14 continued: Comparison of 15N-HSQC of overlay of PDZ1 and 
PDZ1/CN2097 complex and 15N-HSQC overlay of PDZ3 and PDZ3/CN2097 
complex. Each peak denotes a backbone amide of a non-proline residue or side chains of 
Asn, Arg, Gln, and Trp. Greater perturbations in the PDZ3/CN2097 complex indicate 
stronger binding of CN2097 to PDZ3 than to PDZ1. 
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Figure 15. NMR chemical shift perturbations of 15N-PDZ3/unlabeled CN2097 
complex. The average chemical shift perturbations in the backbone amides of PDZ3 
upon CN2097 binding are shown here. The dark blue represents perturbations of more 
than two standard deviations from average, the light blue represents perturbation less than 
two but more than one standard deviation, from average, the cyan represents perturbation 
less than one standard deviation from average, and the green represents perturbation less 
than average. 
 
 The 15N-HSQC overlay of PDZ1long/CaM complex is monodispersed and well 
resolved. Overlaying it on the 15N-HSQC of PDZ1long shows significant perturbations in 
resonance peaks (Figure 16). The peaks that are shifted are not only those representing 
the N-terminal α-helix region but the entire PDZ1long protein. This indicates that the 
CaM not only binds to the N-terminal α-helix but also interacts with the PDZ1 domain. 
The binding of CaM to the N-terminal α-helix of PSD-95 has been previously studied 
(Zhang et al., 2014) using a peptide without the folded PDZ1 domain.  
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Figure 16: 15N-HSQC overlay of PDZ1long/CaM complex on PDZ1long. Each peak 
denotes a backbone amide of a non-proline residue or side chains of Asn, Arg, Gln, and 
Trp. Significant perturbations indicate binding of CaM to the N-terminal α-helix and 
interaction with PDZ1. 
 
The 15N-HSQC overlay of PDZ1long/CaM complex and PDZ1long/CaM/CN2097 
complex shows no significant perturbations in resonance peaks (Figure 17). This 
indicates that CN2097 does not bind to PDZ1 in the presence of CaM.  
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Figure 17: 15N-HSQC overlay of PDZ1long/CaM/CN2097 complex on 
PDZ1long/CaM complex. Each peak denotes a backbone amide of a non-proline residue 
or side chains of Asn, Arg, Gln, and Trp. No significant perturbations indicate that 
CN2097 does not bind PDZ1 in the presence of CaM. 
 
 The 3D- HNCA and HCNO experiments were used to perform a triple resonance 
backbone assignment of PDZ3/CN2097, which are shown in its 15N-HSQC (Figure 18). 
Similarly, CN2097 resonance assignments were obtained using 2D-TOCSY (Figure 19). 
This data was used in software HADDOCK to create a model of complex between the 
PDZ3/CN2097. It can be clearly seen that the β2-β3 loop is not conserved between PDZ1 
and PDZ3 (Figure 20).  
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Figure 18: HSQC of 15N-PDZ3/unlabeled CN2097 complex. Each peak denotes a 
backbone amide of a non-proline residue or side chains of Asn, Arg, Gln, and Trp. The 
backbone assignment of each residue was made using data acquired from 3D- HNCA 
experiment. 
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Figure 19: 2D-TOCSY on CN2097. 
 
 
Figure 20: Overlay of structures of PDZ1 and PDZ3. The cyclic peptide portion of 
CN2097 is shown with sticks.  
 37 
DISCUSSION 
 
PDZ inter-domain interactions 
The ITC data acquired was unreliable in determining binding parameters for 
PDZ1long, PDZ1, PDZ2, and PDZ1+2. There are no ITC data for a comparison to be 
made between CN2097 affinities and effect of the inter-domain interactions. If there were 
inter-domain interactions, ITC results would, in theory, suggest a different binding 
affinity of PDZ1long, PDZ1+2, and PDZ2+3 to CN2097. However, the 15N-HSQC 
spectra acquired helped us overcome this problem. 
The lack of significant perturbations in PDZ1long compared to PDZ1 indicates 
that there are no significant contacts between the N-terminal CaM-binding α-helix and 
the PDZ1 domain (Figure 7). Due to the presence of the α-helix, some minor 
perturbations are bound to be seen, but there are no significant shifts in resonance peaks 
that would have suggested significant interaction in the N-term helix and PDZ1 domain. 
The same is true for PDZ2 and the second inter-domain linker. The lack of significant 
PDZ2+3 perturbations in the PDZ2 region indicates there is no interaction between PDZ2 
and the second inter-domain linker. However, there is an interaction between the second 
inter-domain linker and PDZ3, as evident in NMR spectra (Figure 11). This opens up 
questions on its effect on binding, such as how CN2097 and other ligands will bind PDZ3 
when it is part of the entire PSD-95 protein as opposed to an isolated domain. ITC data 
suggests that the presence of the linker and PDZ2 decrease the binding affinity of 
CN2097 for the PDZ3 domain (Table 1). 
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The uneven peak intensities of PDZ1+2 indicate the presence of inter-domain 
conformational exchanges and interaction between PDZ1 and PDZ2 (Figure 9). The 
peaks do not overlap perfectly, and this might be due to the fact that the inter-domain 
linker between the PDZ1 and PDZ2 is only nine residues long, causing the two domains 
to be close in proximity and thus undergo conformational exchange. This raises questions 
such as how they interact and to what extent does it have any effect on how drugs like 
CN2097 and other ligands bind. 
 
PDZ and drug interactions 
The ITC data would have provided the binding parameters of CN2097 binding to 
the isolated domains. In theory, if the dissociation constant of PDZ1 were smaller than 
PDZ1long, then that would indicate the N-terminal α-helix interferes with ligand binding. 
Likewise, if the dissociation constant of PDZ1 and PDZ2 were each smaller than 
PDZ1+2, then that would also indicate that the binding of CN2097 is affected by protein 
interactions from the other PDZ domains.  
CN2097 binding to PDZ3 is tighter when it is isolated than when PDZ2 and the 
second inter-domain linker are present. This suggests that there is something interfering 
with the binding of CN2097 to PDZ3. The ITC data both support this, as the dissociation 
constant of PDZ3 was smaller than that of PDZ2+3. The NMR data also supports this, as 
the PDZ3 region of PDZ2+3 is significantly perturbed. CN2097 also appears to bind to 
PDZ3 more tightly than to PDZ1. The binding pocket of PDZ3 is located similarly to 
PDZ1, between the second α-helix and second β-sheet. Also similarly, the β2-β3 loop is 
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shown to be affected by ligand association. What is different is that the loop is much 
shorter in PDZ3, which may be the reason why CN2097 binding perturbs PDZ3 more 
strongly than PDZ1. CN2097 also does not appear to bind to PDZ1long in the presence of 
CaM. The implication of this being, in vivo where CaM is abundant and the PDZ 
domains are part of the entire PSD-95 protein, CaM will bind to the N-terminal α-helix 
and interfere with the binding of CN2097 to PDZ1, causing it to preferably bind PDZ3.  
 
Limitations of ITC and NMR 
 ITC is limited by its need for relatively high concentrations of protein and ligand. 
The proteins of interest were not always expressed at the concentration that was 
necessary for a successful experiment, which was typical ~100µM. To achieve a high 
enough concentration, the protein often required concentrating, risking precipitation. The 
need for the ligand to be 10-15x the protein concentration was also a challenge, requiring 
milligrams quantities of CN2097 to meet the 1mM concentration needed when only 
milligrams were available. Measurement times are relatively long and the reagents cannot 
be reused. 
 NMR spectroscopy poses a similar limitation, requiring hundreds of microliters of 
samples at similar protein concentrations. Proteins need to be below a certain size to be 
useful for NMR studies. The proteins used in this study were soluble and small enough to 
be well resolved, although PDZ1+2+3 was rather large at ~40kDa. Another limitation is 
the relatively low sensitivity in comparison to other techniques such as mass 
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spectrometry. The advantage of NMR to mass spectrometry, however, is that NMR can 
provide information on the folded state of proteins. 
 
Future research implications 
In this study, inter-domain interactions between PDZ domains were identified and 
the NMR resonance assignment of PDZ3/CN2097 complex was completed. Both of these 
findings allow for the future development of CN2097 on two fronts. One is research 
towards reducing proteolysis and the other is to improve the drug’s binding affinity. The 
CRIPT peptide that the cyclic peptide of CN2097 was based on was found to bind to 
PDZ3, yet the drug has been developed to bind to PDZ1. Knowing that inter-domain 
interactions exist and may interfere with drug binding, as well as the likelihood of CaM 
limiting drug binding in vivo, it will be interesting to further investigate what effects 
those interactions will have on drug binding. The effects of those interactions may have 
further implications on how the drug can be further developed. 
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